The U.S. Federal Trade Commission (FDA) announced on Tuesday that it is disputing over 300 patent listings across 20 different brand name drugs in an effort to promote competition and lower drug prices. Novo Nordisk’s popular diabetes drug Ozempic is among the drugs with patents that are being challenged.
Originally published on Quartz : Original article